XYLOCAINE 5% W/ GLUCOSE 7.5% Drug Patent Profile

When do Xylocaine 5% W/ Glucose 7.5% patents expire, and what generic alternatives are available?

Xylocaine 5% W/ Glucose 7.5% is a drug marketed by Astrazeneca and is included in one NDA.

The generic ingredient in XYLOCAINE 5% W/ GLUCOSE 7.5% is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xylocaine 5% W/ Glucose 7.5%

A generic version of XYLOCAINE 5% W/ GLUCOSE 7.5% was approved as lidocaine hydrochloride by WOCKHARDT BIO AG on November 18^th, 1982.

Summary for XYLOCAINE 5% W/ GLUCOSE 7.5%

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	42
Clinical Trials:	2
DailyMed Link:	XYLOCAINE 5% W/ GLUCOSE 7.5% at DailyMed

Recent Clinical Trials for XYLOCAINE 5% W/ GLUCOSE 7.5%

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Centre hospitalier de l'Université de Montréal (CHUM)	Phase 4
The University of Texas Health Science Center at San Antonio	Phase 4

See all XYLOCAINE 5% W/ GLUCOSE 7.5% clinical trials

US Patents and Regulatory Information for XYLOCAINE 5% W/ GLUCOSE 7.5%

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	XYLOCAINE 5% W/ GLUCOSE 7.5%	lidocaine hydrochloride	INJECTABLE;SPINAL	010496-002	Jul 7, 1982		DISCN	No	No